Compare Cytokinetics Inc (CYTK) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Orion Office REIT Inc — how do they compare? Cytokinetics Inc trades at $76.57 (market cap $10.63B), while Orion Office REIT Inc trades at $2.75 (market cap $158.01M). The key difference: Cytokinetics Inc is far larger — about 67.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | ONL | |
|---|---|---|
Market Cap | $10.63B | $158.01M |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $3.04 |
52-Week Low | $34.31 | $1.93 |
Enterprise Value | $10.74B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
ONL trades at $2.80, up 1.82% with a bullish technical signal. The company reported mixed Q2 2026 results with an EPS beat but faces fundamental challenges including declining revenue and negative net income margins. Analyst consensus is split 50/50 between Buy and Hold ratings. Recent news highlights strategic review progress and portfolio repositioning efforts.
Outlook remains cautious due to persistent losses and revenue decline, though low P/B ratio and dividend payments offer some value. Key risks include continued negative profitability and high debt levels. The stock presents speculative value for investors tolerant of turnaround execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
